Undifferentiated and poorly differentiated thyroid tumors are responsible for more than half of thyroid cancer patient deaths in spite of their low incidence. Conventional treatments do not obtain substantial benefits, and the lack of alternative approaches limits patient survival. Additionally, the absence of prognostic markers for well-differentiated tumors complicates patient-specific treatments and favors the progression of recurrent forms. In order to recognize the molecular basis involved in tumor dedifferentiation and identify potential markers for thyroid cancer prognosis prediction, we analysed the expression profile of 44 thyroid primary tumors with different degrees of dedifferentiation and aggressiveness using cDNA microarrays. Transcriptome comparison of dedifferentiated and well-differentiated thyroid tumors identified 1031 genes with >2-fold difference in absolute values and false discovery rate of o0.15. According to known molecular interaction and reaction networks, the products of these genes were mainly clustered in the MAPkinase signaling pathway, the TGF-b signaling pathway, focal adhesion and cell motility, activation of actin polymerization and cell cycle. An exhaustive search in several databases allowed us to identify various members of the matrix metalloproteinase, melanoma antigen A and collagen gene families within the upregulated gene set. We also identified a prognosis classifier comprising just 30 transcripts with an overall accuracy of 95%. These findings may clarify the molecular mechanisms involved in thyroid tumor dedifferentiation and provide a potential prognosis predictor as well as targets for new therapies.
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Introduction
Approximately 122 000 new cases of thyroid carcinoma are diagnosed each year worldwide, and more than 90% have a follicular cell origin. Malignant tumors of thyroid follicular cells have been classified either as well-differentiated thyroid carcinoma (WDTC), which is composed of papillary and follicular thyroid carcinoma (PTC and FTC, respectively), or as undifferentiated/ anaplastic thyroid carcinoma (ATC). The majority of WDTC are indolent malignancies with a 10-year survival of up to 90% (Randolph and Daniels, 2002) . In contrast, ATC is one of the most aggressive human malignancies. Despite its low frequency (o5% of all thyroid carcinomas), ATC is responsible for more than half of thyroid carcinoma deaths, with a mean survival of 6 months after diagnosis (Ain, 1999) . However, several studies (Sakamoto et al., 1983; Sobrinho-Simoes et al., 2002) confirm the existence of a class of tumors intermediate between WDTC and ATC, namely poorly differentiated thyroid carcinomas (PDTC), which represent entities in progress from a pre-existing WDTC to ATC, often with a similar outcome as ATC.
Primary treatment of follicular cell-derived tumors, which has not substantially changed in recent decades, is mainly based on surgical treatment, ablative 131 I treatment, and suppressive L-thyroxine administration (Vini and Harmer, 2002) . Benefits obtained from chemotherapy and radiation therapy remain only marginal (Cooper et al., 2006) , and metastases, recurrent disease and poorly differentiated/anaplastic tumors still pose major challenges to clinicians. There is a lack of alternative treatments for tumors with a poor response to conventional treatment, or those with a poor degree of differentiation. We are thus in need of new approaches that may lead to improved disease management. Microarray analysis of geneexpression patterns has provided a way to identify molecular events related to specific tumor types and to specific cancer processes, such as metastasis, proliferation and angiogenesis (Glinsky, 2006) . Numerous studies also have demonstrated its potential for the identification of molecular signatures associated with different clinical features (van de Vijver et al., 2002; Huang et al., 2003) , that could help identify novel targets for therapy.
In the present study, using one of the largest series of frozen thyroid carcinoma tumors published to date, we have carried out an extensive microarray analysis followed by an innovative bioinformatics approach, the GEPAS package ; http:// www.gepas.org), to process and interpret the results taking into account the clinical data. We have compared the gene-expression profiles, obtained using the CNIO Oncochip, of ATC and PDTC cases versus WDTC samples. We first selected the genes differentially expressed in ATC/PDTC versus FTC and ATC/PDTC versus PTC, as representing dedifferentiation and clinical aggressiveness features, and analysed their functional implications by identifying molecular pathways involved. We were able to define cellular processes important for malignant progression of thyroid cancer. Moreover, we found a prognosis signature that recognizes not only undifferentiated and poorly differentiated tumors, but also recurrent and metastatic WDTC. These results may provide new perspectives for diagnosis, treatment and design of new therapeutic strategies for thyroid carcinoma patients with poor prognosis.
Results
Differential gene expression related to tumor dedifferentiation Genes found differentially expressed in the two pairwise comparisons ATC/PDTC versus FTC and ATC/PDTC versus PTC, were assumed to be functionally related to dedifferentiation and clinical aggressiveness. Genes differentially expressed in only one of the comparisons were supposed to be related to the specific etiology of each WDTC class.
Taking into account only transcripts common to both pairwise comparisons, 742 clones corresponding to 594 genes and 83 ESTs were overexpressed and 678 clones corresponding to 535 genes and 78 ESTs were underexpressed in the ATC/PDTC tumor set.
Functional profiling: pathways and gene families involved in malignancy progression in thyroid cancer The FatiScan test for gene set enrichment analysis was applied to analyse the transcriptional profiles of ATC/ PDTC versus WDTC. We observed a significant upregulation of the biological process 'cell cycle progression' (adjusted P-valueo0.05), and a downregulation of hormone biosynthesis, a thyroid-specific function (adjusted P-valueo0.05). 'Cell cycle progression' includes mitosis, DNA replication and repair, microtubule and actin-filament-based processes, and chromosome reorganization and biogenesis.
The additional analysis of gene biological function revealed gene enrichment in several pathways and KEGG terms. Interestingly, the MAPkinase signaling pathway, the TGF-b signaling pathway, 'focal adhesion and cell motility', and 'activation of actin polymerization' presented an overexpression of core genes for pathway activation and an underexpression for inhibitors of the same processes. Table 1 shows the differentially expressed genes (FDR o0.15, >2-fold) within these functional categories. We also found that some of the regulated genes with similar transcription patterns (significant over-or underexpression for ATC/ PDTC) belonged to the same gene family (Table 2) .
A predictor of clinical prognosis for WDTC Using an SVM-learning algorithm and F-ratio gene selection method, the Prophet program defined a prediction classifier of only 30 transcripts (corresponding to 23 genes and 6 ESTs; Table 3 ) that generates the lowest unbiased cross-validation error (0.0455%) for this tumor series ( Figure 1a) . A hierarchical unsupervised analysis ( Figure 1b ) using the set of genes selected by the predictor visually shows the discrimination among tumors with different clinical outcomes.
Validation of gene expression
Validation of microarray results was done in 2 ATC, 3 PDTC and 17 WDTC (3 FTC and 14 PTC), using predesigned TaqMan probes of four genes from the signature of the predictor: ubiquitin-conjugating enzyme E2C (UBE2C), effector cell peptidase receptor 1 (survivin, BIRC5), actin-binding protein (anilin, ANLN) and centromere protein A (CENPA). BIRC5, CENPA, UBE2C and ANLN showed a higher expression in ATC and PDTC cases. These results validated those obtained by using microarray technology.
Discussion
To date, only a few studies on ATC and PDTC have been published and, due to the difficulty to obtain tumor samples, most of them use cell lines. In the present study, we have identified molecular processes significantly involved in the complex event of malignancy progression in thyroid cancer, using a large frozen tissue panel of human primary thyroid tumors in different dedifferentiation stages (7ATC, 6PDTC and 31WDTC). We were able to identify an original molecular prognosis signature of 30 transcripts by means of expression profiling and new high accuracy bioinformatics tools able to solve common limits of multiple testing analysis and a relatively small sample size.
Expression and functional profiling highlight the molecular basis of the dedifferentiation process A significant upregulation of 'Cell cycle progression' was found by the functional profiling of ATC/PDTC comparisons, as expected for these aggressive tumors. In addition, the analysis related to the dedifferentiation process confirmed over-and underexpression of genes previously described to indicate poor prognosis for thyroid tumors (Rocha et al., 2003; Onda et al., 2004; Motti et al., 2005; Pallante et al., 2005; Sorrentino et al., 2005; Zou et al., 2005;  Table 4 ).
Moreover, our transcriptional profile correlate with poor prognosis features previously described for different types of malignant tumors (Glinsky, 2006) such as the increased expression of members of the inhibitor of apoptosis protein family (BIRC5), activation of mitotic spindle checkpoint proteins (BUB1, BUB3, KNTC2, MAD2 (MAD2L1), PLK4 and AURORA A (STK6)) and high levels of cell cycle control/marker proteins (CCNB2, CCNA2 and CDC2). Finally, we found that our ATC/PDTC series had a deregulation of critical genes for thyroid hormone synthesis, such as the overexpression of ARRB2 (b-arrestin 2; Voigt et al., 2000) , which is implicated in the desensitization of thyroid-stimulating hormone receptors (TSHR), the underexpression of RAB5A, which participates in the thyroglobulin production (TG; Croizet-Berger et al., 2002) , and a diminished expression of TG and PAX8, which has also been observed before in ATC/PDTC series (Onda et al., 2004) . Furthermore, the expression of HHEX, a gene related to thyroid morphogenesis and differentiation, was decreased in ATC/PDTC. All these data are consistent with the TSHR pathway alteration and loss of thyroid-specific function in the dedifferentiated thyroid neoplasias.
Functional profiling and gene family analysis reveal the deregulation of molecular pathways related to malignancy progression of thyroid cancer We observed that the MAP-kinase signaling pathway, which includes the well-known molecular lesions involved in WDTC (Nikiforova et al., 2003) was strongly affected through an overexpression of key pathway activators and an underexpression of negative regulators (Table 1) . Deregulation of this pathway is critical for the evolution of thyroid neoplasia, and its restoration could constitute a promising therapeutic approach for the dedifferentiated carcinoma.
Other pathways showing important alterations were the interconnected TGFb signaling pathway, focal adhesion and regulation of the actin cytoskeleton. The TGFb signaling pathway has been associated with the epithelial-to-mesenchymal (EMT) transition in later stages of cancer (Siegel and Massague, 2003) and more recently, with papillary thyroid tumor invasion (Vasko et al., 2007) . EMT is a multi-step process involving dissolution of tight and adherent junctions, cytoskeletal reorganization, loss of cell polarity, repression of epithelial markers and upregulation of mesenchymal proteins (Grunert et al., 2003) . In our ATC/PDTC series, we observed an overexpression of the E3 ubiquitin ligase SMURF1 that targets RhoA, producing tight junction dissolution and actin cytoskeleton remodeling (Wang et al., 2003) . This last event may be reflected in our tumor profile by the overexpression of several genes involved in cytoskeleton remodeling (Table 1) . Moreover, the transcriptional ATC/PDTC profile also showed overexpression of TWIST1 and downregulation of CDH1, both important regulators of EMT in the metastatic and invasive process (Yang et al., 2004; Zavadil and Bottinger, 2005) . In addition, several mesenchymal protein coding genes (members of the collagen and laminin protein families; Table 2 ) were overexpressed as expected for tumor invasion and angiogenesis (Sherman-Baust et al., 2003; Tang et al., 2006 ). An overexpression of various genes of the metalloproteinase (MMP) family was also observed (Table 2) and they have been associated with degradation of the basal lamina components, TGFb pathway upregulation and tumor invasion (Chambers and Matrisian, 1997) .
Other proteins involved in invasion are the chemokines, which have been detected in a wide range of tumors and have been suggested to exhibit a cancer-specific Abbreviations: Chr, chromosome; NPPTC, non-poor prognosis thyroid carcinoma; PPTC, poor prognosis thyroid carcinoma.
Molecular profiling in thyroid cancer C Montero-Conde et al expression pattern (Slettenaar and Wilson, 2006) . We found that CXCL3, CXCL10 and CXCL11 were significantly overexpressed in ATC/PDTC. The transcription of CXCL10 and 11 is induced by interferon-g, which was also upregulated in our ATC/PDTC series. Interestingly, we observed an overexpression of the MAGEA subfamily of cancer testis antigens (MAGEA1-4, MAGEA6, MAGEA8 and MAGEA10-11). These genes, together with other subfamily members of MAGE antigens, are normally expressed only in placenta and male germ cells, but serve as unique tumor markers in several types of malignancies. It has been proposed that MAGE-derived antigen mRNA expression is correlated with in vitro acquisition of paclitaxel and doxorubicin resistance, and higher malignancy (Duan et al., 2003) . This also occurred in our thyroid carcinoma series, indicating that ATC/PDCT could be candidates for a MAGE-based therapy. In fact, recent clinical trials in non-thyroid tumors have shown promising results (Burgdorf et al., 2006) .
Identification of a molecular prognosis signature for thyroid follicular cell tumors
In recent years, numerous mathematical algorithms have been proposed to find the minimal number of transcripts able to discriminate clinical features from global expression profiles of different sets of tumors, allowing the improvement of the prognostic procedure (van de Vijver et al., 2002) . However, these tools often present errors related to gene selection bias (Ambroise and McLachlan, 2002 ) that can lead to severe underestimations of prediction errors. We used (Medina et al., 2007) , a tool unique in its kind, which implements a cross-validation strategy that renders unbiased error estimations. By means of this tool, we obtained a molecular signature including only 23 genes (Table 3 ) and 6 ESTs that can properly distinguish ATC/PDTC and recurrent-WDTC from good prognosis WDTC. It was especially interesting that a PTC case diagnosed as Diffuse Sclerosing Variant (DSV) (04T117), with an initial TNM stage of T4N1M1, was classified as non-poor prognosis tumor by current molecular signature. DSV is a rare variant of papillary thyroid carcinoma, which is characterized by early tumor onset (mean age, 29 vs 46 years for classic PTC), large tumors and higher incidence of cervical node metastases than classic PTC (80 vs 43%). It should be noted that despite the aggressive clinicopathologic features of DSV, it has a prognosis similar to that of classic PTC (the overall disease-specific survival rate is 93%; Fujimoto et al., 1990; Lam and Lo, 2006) . In fact, this patient is free of disease after 5 years of follow-up.
On the other hand, only two WDTC cases (FTC_04T231 and PTC_04T116), free of disease at the moment they were included in the study, were classified as poor prognosis tumors. These patients had less than two years of follow-up, and a future relapse cannot be ruled out. Thus, although further series of thyroid tumors and prospective studies are needed to validate this signature, this finding is of great interest for diagnosis and therapy improvement through the classification of patients according to prognosis.
Potential clinical implications of the current findings
The findings of the present study represent a significant contribution toward understanding the complex molecular mechanisms involved in progression and dedifferentiation of thyroid follicular cell tumors. There is a lack of alternative treatments for thyroid follicular cellderived tumors with a poor response to conventional therapy; thus, it is desirable to identify the molecular pathways involved in thyroid cancer pathogenesis since this may lead to improvement in disease management. In the present paper, we describe new molecular pathways and markers specifically altered in PDTC and ATC that may allow the identification of novel targets for therapies. Furthermore, the poor prognosis molecular profile identified in this study demonstrates a relationship between the transcriptional pattern and the clinical behavior and pathology stage. This should contribute to a better prediction of recurrence and mortality, with an obvious improvement in the stratification of treatment and clinical follow-up.
Material and methods
Tissue specimens and clinical data Seven ATC, 6 PDTC and 31 WDTC (7 FTC and 24 PTC) were collected from unrelated patients from Hospital de la Santa Creu i Sant Pau, Hospital de Sabadell, Hospital Arnau de Vilanova and other Hospitals through the Spanish National Tumor Bank Network coordinated by CNIO. The tissues were immediately frozen in liquid nitrogen and stored at À80 1C until RNA extraction. Five frozen normal thyroid tissues were obtained from laryngectomies of consenting patients without thyroid disease. Three independent pathologists evaluated each diagnosis and defined the percentage of tumor tissue by hematoxylin/eosin (H&E) staining of the sections. Only samples with more than 80% tumor cells were included in the study; when possible, samples were manually microdissected to remove areas with less than 80% tumor cells.
The clinicopathologic characteristics of the cases are detailed in Supplementary Table 1 . The 31 patients with WDTC had a follow-up that ranged from 8 months to 19 years (mean 3.43 years). Twenty-eight of them were disease-free at the last medical control, whereas there was evidence of tumor recurrence in three patients. These three cases were designated as 'poor prognosis WDTC'.
The six PDTC cases were classified in this category according to the criteria proposed by the WHO, 2004 (DeLellis et al., 2004 , which include the presence of three different histologic patterns (insular, trabecular or solid). The six tumors exhibited an infiltrative pattern of growth, necrosis and obvious vascular invasion and none had a minor component of papillary or follicular carcinoma. However, nuclear features similar to papillary carcinomas were focally detected in two tumors (04T141 and 05T205), and a further two (04T143 and 04T144) showed focal of architectural configuration similar to follicular carcinomas.
RNA isolation
Total RNA was extracted using TriReagent (Molecular Research Center, Cincinnati, OH, USA) and purified using an RNeasy kit (Qiagen, Inc., Valencia, CA, USA). Purity and integrity of the RNA was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA), and degraded samples were discarded. Concentration was determined using a Nanodrop ND-1000 spectrophotometer.
cDNA synthesis, labeling, hybridization and detection For each sample, 4 mg of total RNA were amplified by doublestrand cDNA synthesis (Life Technologies, Inc.), followed by T7-based in vitro transcription (Ambion, Austin, TX, USA) as previously described (Alonso et al., 2007) . Amplified RNA (aRNA) was labeled with cyanine 5-conjugated dUTP (Cy5) whereas aRNA from Universal Human Reference RNA was labeled with cyanine 3-conjugated dUTP (Cy3). The CNIO Oncochip v2 was used to perform the co-hybridization. Slides were washed, dried and scanned in a Scanarray 5000XL scanner (GSI Lumonics, Kanata, Ontario, Canada).
The CNIO Oncochip v2 is a cDNA microarray which contains 11 675 human clones representing 9348 known genes and uncharacterized expressed sequence tags (ESTs). The probes were selected on the basis of their proven or putative involvement in cancer. Internal controls and at least one duplicate per clone are present in order to assess the reproducibility and specificity of the assay.
Data analysis
Normalization and preprocessing Two channel ratios (Cy5/ Cy3) for each array spot were generated and quantified using GenePix Pro 5.1. (Axon Instruments, Inc., Union City, CA, USA). Data were normalized by the LOWESS method as implemented in the GEPAS package . Half of the median background was subtracted from each spot. Normalized data were log2 transformed. Spots in defective areas of the microarray, or with halo morphology or with intensities (sum of medians of two channels) below the sum of the mean backgrounds, were considered missing values. Inconsistent replicates of clones were discarded and consistent duplicates were averaged. Gene patterns containing missing values were discarded.
Differentially expressed genes associated to dedifferentiation and aggressiveness To identify specific transcripts related to dedifferentiation and aggressiveness, two distinct pairwise comparisons were made between ATC/PDTC and each class of WDTC (FTC and PTC). A t-test was carried out as implemented in GEPAS . P-values were corrected for multiple testing using the method proposed by Hochberg and Benjamini for controlling the false discovery rate (FDR; Benjamini and Yekutieli, 2005) . Genes showing a FDR valueo0.15 and a more than two-fold difference in absolute values for both comparisons were considered differentially expressed.
Functional profiling of dedifferentiation and aggressiveness
Gene set enrichment analysis (Mootha et al., 2003) is the most powerful strategy to discover biological processes differentially regulated in ATC/PDTC and WDTC. It is based on the study of the distribution of gene sets sharing functional annotations across a list of genes ranked according to differential expression. We ranked the genes according to differential expression in ATC/PDTC and WDTC, correcting for gender and age effects using the Limma package from bioconductor (Gentleman et al., 2004) . Since this scenario is more complex than the simple case-control implemented in the original proposal of the method, we used a generalization of the gene set enrichment test, the FatiScan, which is independent of experimental design and only uses a list of ranked genes. This test is implemented in the Babelomics package (Al-Shahrour et al., 2006; http:// www.babelomics.org) and allows to test different biological terms (Gene Ontology, KEGG pathway, Biocarta pathways, functional motifs, Swissprot keywords, transcription factor binding sites and cis-regulatory elements).
Additional functional enrichment of the differentially expressed gene set was assessed using the FatiGOplus tool, also implemented in the Babelomics package (Al-Shahrour et al., 2006) , as well as manual exhaustive searches in PubMed and the Entrez Gene database.
A predictor of clinical prognosis The Prophet program (Medina et al., 2007) from the GEPAS package was used to build a clinical outcome predictor of thyroid follicular cell tumors. Prophet uses a cross-validation schema specially designed to produce unbiased cross-validation errors, and implements different state-of-the-art methods for gene selection and prediction. In the current study, the Support Vector Machines (SVM) algorithm (Brown et al., 2000) with the radial basis function kernel method was used for classification rule generation, and the F-ratio gene filter approach for gene selection. All available tumors were included. Hierarchical clustering and Tree View from GEPAS (Herrero et al., 2001) were used to visualize the predictor results.
Validation of microarray data by quantitative real-time RT-PCR Four genes from the poor prognosis signature were randomly selected to validate the microarray results using 22 samples (half of the total used in the initial study). Reverse transcription was performed using 1 mg total RNA, Oligo(dT) 23 and M-MLV Reverse Transcriptase (Promega Corporation, Madison, USA). PCRs were done on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA) using Assay-on-Demand Taqman MGB probes (Applied Biosystems) as described by the manufacturer. All analyses were performed in triplicate, and relative RNA levels were determined using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal control; 5 normal thyroid tissue samples were used to construct the standard curves.
